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The glutamate hypothesis of schizophrenia, proposed over two decades ago, originated fol-
lowing the observation that administration of drugs that block NMDA glutamate receptors,
such as ketamine, could induce schizophrenia-like symptoms. Since then, this hypothesis
has been extended to describe how glutamate abnormalities may disturb brain function
and underpin psychotic symptoms and cognitive impairments.The glutamatergic system is
now a major focus for the development of new compounds in schizophrenia. Relationships
between regional brain glutamate function and symptom severity can be investigated using
proton magnetic resonance spectroscopy (1H-MRS) to estimate levels of glutamatergic
metabolites in vivo. Here we briefly review the 1H-MRS studies that have explored rela-
tionships between glutamatergic metabolites, symptoms, and cognitive function in clinical
samples.While some of these studies suggest that more severe symptoms may be associ-
ated with elevated glutamatergic function in the anterior cingulate, studies in larger patient
samples selected on the basis of symptom severity are required.
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INTRODUCTION
Accumulating evidence suggests that glutamatergic dysfunction
may contribute to the pathogenesis of schizophrenia, and the
symptoms and cognitive deficits associated with the disorder (1).
The glutamatergic system presents an attractive therapeutic tar-
get, as dopaminergic antipsychotics have little effect on negative
symptoms or cognitive impairment, yet these features are better
predictors of social and functional outcome than positive symp-
toms (2, 3). Here we briefly review the existing evidence linking
abnormal glutamatergic transmission to cognitive, negative, and
positive symptoms of schizophrenia.
The observation that administration of antagonists at the N -
methyl-d-aspartate glutamate receptor complex (NMDAR) such
as phencyclidine (PCP) or ketamine to healthy volunteers induces
effects which resemble aspects of schizophrenia symptomatology
forms a cornerstone of the glutamate hypothesis of schizophre-
nia (4–6). NMDAR antagonists also worsen positive, negative,
and cognitive symptoms in patients with schizophrenia (7, 8).
While dopamine-stimulating drugs such as amphetamine also
produce positive “psychotic”-like effects, negative-type symp-
toms, and cognitive deficits are far more prominently elicited by
ketamine than amphetamine administration (9). Neuroimaging
studies indicate that these effects of ketamine are mediated by
changes in activity in the frontal and cingulate cortices and the
thalamus (10–13).
While pharmacological studies have provided evidence linking
NMDAR dysfunction to these symptom domains, direct asso-
ciations between glutamatergic function and symptom severity
may be provided by neuroimaging studies. In a single photon
emission tomography study using the NMDAR radiotracer 123I-
CNS-1261 in schizophrenia, the availability of NMDAR in the
hippocampus was negatively associated with the severity of symp-
toms, especially negative symptoms (14). A ketamine challenge
study in healthy volunteers using the same radiotracer linked
regional NMDAR binding to the induction of negative (but not
positive) symptoms, particularly in the thalamus (15). These
approaches are currently limited by a lack of availability of suitable
radiotracers (1).
An alternative is to use proton magnetic resonance spec-
troscopy (1H-MRS) to estimate the concentration of glutamater-
gic metabolites. MRI scanners with field strengths of 3 T or
above can resolve glutamate, at least for the most part, from its
metabolite glutamine (16). At lower field strengths glutamate and
glutamine are reported in combination, as Glx. A limitation of
1H-MRS is that the glutamate concentration estimates are not
specific to neuronal glutamate, and that changes in glutamate
levels cannot be specifically attributed to altered neurotransmis-
sion over other metabolic processes (17). However the majority
(∼80%) of glutamine synthesis reflects cycling of neurotrans-
mitter glutamate (17), and clinical studies at 4 T in minimally
treated patients with schizophrenia have reported higher Gln/Glu
ratios (18) or higher glutamine levels (19) in the anterior cingu-
late cortex (ACC). This is consistent with increased glutamatergic
neurotransmission, but could also result from a deficiency in the
conversion of glutamine to glutamate. However the majority of
1H-MRS studies in psychosis have used field strengths <4 T and
thereby were unable to accurately quantify glutamine concentra-
tions. Thus, the results from these studies at lower field strengths
cannot be specifically attributed to changes in glutamate neu-
rotransmission. Nonetheless, increases in frontal glutamatergic
neurotransmission in schizophrenia are broadly consistent with
the NMDA receptor hypofunction hypothesis, as administration
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of NMDAR antagonists to rats increases glutamate release as
detected by microdialysis (20), and 1H-MRS studies report ele-
vated Gln/Glu ratios (21), or increased glutamate levels with no
changes in glutamine (22). 1H-MRS studies with ketamine in man
at 4 T reveal increased ACC glutamine (23), and at 3 T reveal
increased ACC glutamate (24). One mechanism through which
increases in glutamate release may occur is via NMDAR dysfunc-
tion on GABA-ergic interneurons, leading to the disinhibition
of glutamatergic pyramidal cells, as described by the NMDAR
hypofunction hypothesis (25).
Individual 1H-MRS glutamate studies in schizophrenia have
produced some inconsistent findings. In general, studies at higher
field strengths suggest that frontal glutamine function is elevated
in the early stages of psychosis (18, 19), whereas the findings
in chronic schizophrenia are more variable (26–30). This could
reflect effects of antipsychotic medication. For example, one cross-
sectional and one longitudinal study reported higher Glx levels
in the PFC of unmedicated, but not medicated schizophrenia,
in comparison to controls (31, 32), although longitudinal stud-
ies have reported no effect of medication on anterior cingulate
glutamate or glutamine levels (18, 33, 34). It could be that symp-
tom severity contributes to variability in glutamatergic metabolites
between patients early or late in the illness, as samples involv-
ing patients in the early phase of psychosis usually comprise
non- or minimally medicated patients who are relatively symp-
tomatic, whereas studies in chronic schizophrenia often involve
patients who have been treated for long periods and have less
severe or more stable symptoms (1). In relation to this, a recent
meta-analysis of 1H-MRS glutamatergic studies in major depres-
sive disorder found lower levels of Glx in the ACC which were
only significant when remitted patients were excluded from the
analysis (35).
In order to better understand the possible relationships between
1H-MRS glutamate, glutamine, and Glx levels and symptom sever-
ity, we identified publications that have reported associations
with severity along symptom domains. These included studies in
individuals at risk of psychosis, and patients with first-episode
psychosis or established schizophrenia (Table 1).
RELATIONSHIPS BETWEEN GLUTAMATE FUNCTION AND
POSITIVE SYMPTOMS
Several studies have investigated associations between regional
glutamatergic metabolite levels and the severity of positive psy-
chotic symptoms (Table 1), and most found no association
between regional Glx, glutamate or glutamine levels and positive
symptom severity, in either high genetic or clinical risk popula-
tions (36, 37), first-episode psychosis (18, 19, 37–40) or chronic
schizophrenia (26–28, 30, 41–46).
However, many of these studies involved small patient sam-
ples, relied on post hoc correlational analyses, and patients in
whom the severity and/or the variance in severity of symptoms
was low, due to either being sub-clinical threshold in the at
risk studies or due to the presence of antipsychotic medication
in established schizophrenia. A recent study pooling both med-
icated and unmedicated patients,where unmedicated patients pos-
sessed elevated Glx in medial prefrontal cortex (mPFC), detected
an association between positive symptom severity and mPFC
Glx, although this did not survive correction for multiple com-
parisons (31). Another study in the PFC found that treatment
reduced the level of Glx/Cr in chronic patients, and associated
the change in Glx with improvement in total BPRS score (32).
Moreover a recent study found that 4 weeks of antipsychotic
treatment in first-episode psychosis patients reduced Glx in the
striatum, and this was associated with improvement in PANSS
score (47).
A notable exception is the study of Ota et al. (48), which directly
compared patients experiencing exacerbated psychotic symptoms
to healthy controls and stable patients, and found that increases in
Glx in inferior parietal white matter were specific to the group cur-
rently experiencing exacerbated psychotic symptoms (48). In line
with this, our own studies which have compared glutamate levels
in patients according to symptom severity have found higher ACC
glutamate levels in first-episode psychosis patients who are still
symptomatic following treatment compared to those in remission
(38) and in patients with treatment-resistant schizophrenia com-
pared to those who respond to medication (49). These differences
may be independent of medication effects, as groups either did not
differ according to medication (38, 49) or the symptomatic group
were actually receiving higher medication doses (48), and as lon-
gitudinal studies have not reported changes in cortical glutamate
in relation to changes in positive symptoms following antipsy-
chotic treatment (18, 33, 34). This suggests that glutamate and
Glx levels may be selectively elevated in patients whose positive
symptoms are not well controlled by conventional antipsychotic
medication.
RELATIONSHIPS BETWEEN GLUTAMATE FUNCTION AND
NEGATIVE SYMPTOMS
We recently reported that greater severity of PANSS negative symp-
toms was associated with higher levels of glutamate in the ACC in
first-episode psychosis (38). Although there were several method-
ological differences, this contrasts with the study of Reid et al. (26),
which reported that negative symptoms were associated with lower
levels of ACC Glx in chronic schizophrenia. Other studies inves-
tigating correlations between ACC glutamatergic metabolites and
negative symptoms have found no significant relationship (18,
19, 28, 42, 46, 50). We are not aware of any studies which have
specifically compared regional levels of glutamatergic metabo-
lites in patient groups selected according to differences in negative
symptom severity.
As listed in Table 1, in brain regions other than the ACC
many studies have failed to detect significant relationships between
negative symptoms and regional glutamate, glutamine, or Glx lev-
els in high genetic or clinical risk groups (36, 37), first-episode
psychosis (18, 37, 39, 40), or chronic schizophrenia (27, 30,
31, 41, 44, 45, 48).
A general consideration of studies investigating relationships
between glutamate markers and positive and negative symptoms
is the scale used to score symptom severity. As detailed in Table 1,
scores on a number of scales have been used and while these scales
are highly correlated there are also some important differences
in the clinical items included (51). As most studies examining
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Table 1 | Summary of articles reporting high levels of glutamate metabolites associated with greater or lesser severity of symptoms.
Reference Field strength Population n Brain region Metabolite Measure Direction
Tandon et al. (54) 1.5 Familial high
risk
23 Thalamus Glx SIPS +
CSS NS
Caudate Glx SIPS, CSS +
ACC Glx SIPS, CSS NS
Yoo et al. (36) 1.5 GHR 22 ACC, DLPFC, thal Glx PANSS, BPRS NS
de la Fuente-Sandoval
et al. (37)
3 ARMS+drug
naïve FE
36 Associative striatum,
cerebellar cortex
Glu PANSS, SIPS NS
de la Fuente-Sandoval
et al. (47)
3 FE 24 Associative striatum Glu PANSS +
Cerebellar cortex Glu, Glx PANSS NS
Egerton et al. (38) 3 FE 32 ACC Glu/Cr PANSS negative +
PANSS positive NS
Thalamus Glu/Cr PANSS NS
Ota et al. (48) 1.5 Chronic
(+1 FE)
46 Inferior parietal Glx PANSS positive +
Middle frontal Glx PANSS NS
Ohrmann et al. (42) 1.5 Chronic 43 ACC, DLPFC Glx PANSS, CDSS, CGI NS
Tayoshi et al. (28) 3 Chronic 30 ACC, basal ganglia Glu, Gln PANSS NS
Wood et al. (30) 3 Chronic 15 Dorsal, rostral
cingulate
Glx PANSS NS
Kegeles et al. (31) 3 Chronic 32 mPFC (inclu ACC) Glx PANSS negative NS
PANSS positive + #
Szulc et al. (62) 1.5 Chronic 42 Frontal lobe Glx/Cr PANSS +
Ohrmann et al. (41) 1.5 Chronic 39 DLPFC Glx PANSS NS
Ongur et al. (50) 4 Chronic 17 ACC, POC Gln/Glu PANSS, MADRS, YMRS NS
Stanley et al. (39) 1.5 FE 14wk
treatment
37 DLPFC Gln SANS, SAPS NS
Bartha et al. (40) 1.5 FE 10 mPFC (inclu ACC) Glu, Gln SANS, SAPS NS
Theberge et al. (19) 4 FE 21 ACC, thal Glu, Gln SANS, SAPS NS
Bustillo et al. (18) 4 FE Min treated 14 ACC, thal Gln/Glu SANS, SAPS NS
Bustillo et al. (43) 4 Chronic 30 Whole brain slice Glx SANS −
SAPS NS
Olbrich et al. (67) 2 FE 9 DLPFC Glu SANS, BPRS −
Hippocampus Glu SANS, BPRS NS
Shirayama et al. (27) 3 Chronic 19 mPFC (inclu ACC) Gln/Glu SANS, BPRS NS
Rowland et al. (44) 3 Chronic 20 mPFC, inferior
parietal
Glx SANS, BPRS NS
Rowland et al. (46) 3 Chronic 21 ACC, CSO Glx SANS, BPRS NS
Choe et al. (32) 1.5 Chronic 34 PFC Glx/Cr BPRS +
Reid et al. (26) 3 Chronic 26 ACC Glx BPRS negative −
BPRS positive NS
(Continued)
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Table 1 | Continued
Reference Field strength Population n Brain region Metabolite Measure Direction
Reid et al. (45) 3 Chronic 35 Substantia nigra Glx/Cr BPRS NS
Tandon et al. (54) 1.5 Familial high
risk
23 ACC, thal, caudate Glx WCST NS
Rusch et al. (53) 2 FE+Chronic 29 Hippocampus Glu WCST +
Shirayama et al. (27) 3 Chronic 19 mPFC (inclu ACC) Gln/Glu WCST, DSDT +
Stroop, VF, IGT NS
Ohrmann et al. (42) 1.5 Chronic 43 ACC Glx WCST −
ACC, DLPFC Glx AVLT NS
Ohrmann et al. (55) 4 FE+Chronic 35 DLPFC Glx AVLT −
Kegeles et al. (31) 3 Chronic 32 mPFC (inclu ACC) Glx N-back NS
Reid et al. (26) 3 Chronic 26 ACC Glx RBANS NS
Reid et al. (45) 3 Chronic 35 Substantia nigra Glx/Cr RBANS NS
Rowland et al. (44) 3 Chronic 20 mPFC, inferior
parietal
Glx RBANS NS
Rowland et al. (46) 3 Chronic 21 ACC, CSO Glx RBANS NS
Bustillo et al. (43) 4 Chronic 30 Whole brain slice Glx Combined neuropsych −
Yoo et al. (36) 1.5 GHR 22 ACC, DLPFC, thal Glx GAF NS
Tibbo et al. (59) 3 GHR 20 mPFC Glx/Cr GAF −
Egerton et al. (38) 3 FE 32 ACC Glu/Cr GAF +
Egerton et al. (38) 3 FE 32 Thalamus Glu/Cr GAF NS
Shirayama et al. (27) 3 Chronic 19 mPFC (inclu ACC) Gln/Glu GAF NS
Tebartz van Elst et al.
(60)
2 Chronic 21 DLPFC Glu GAS +
Aoyama et al. (34) 4 Chronic 17 Thalamus Total Gln+Glu LSPR −
# Did not survive correction for the six comparisons (PANSS total, positive, and negative symptom subscales in two regions for each neurochemical).
Index: + denotes a positive relationship where higher levels of glutamate were associated with greater symptom severity or worse overall functioning; − denotes a
negative relationship where higher levels of glutamate were associated with lesser symptom severity or better overall functioning. NS, not significant; ACC, anterior
cingulate cortex; POC, parieto-occipital cortex; DLPFC, dorsolateral prefrontal cortex; MPFC, medial prefrontal cortex;Thal, thalamus; CSO, centrum semiovale; GHR,
genetic high risk; RBANS, repeatable battery for the assessment of neuropsychological status; WCST, Wisconsin card sorting test; DSDT, the digit span distraction
test;TMT, trail making test; IGT, Iowa gambling task; VF, verbal fluency; AVLT, auditory verbal learning test; BPRS, brief psychiatric rating scale; GAF, global assessment
of functioning; CGI, clinical global impression scale; GAS, global assessment scale; SIPS, structured interview for prodromal symptoms; CSS, Chapman schizotypy
scales; CDSS, Calgary Depression Scale for Schizophrenia; LSPR, life skills profile rating.
relationships between brain glutamate measures and symptoms
have relied on post hoc correlational analysis, it is of note that
additional items are included on the SAPS/SANS compared to the
PANSS, which in turn has additional items compared to the BPRS.
Therefore use of the SAPS/SANS may be preferable as they provide
a more detailed assessment of symptoms.
RELATIONSHIPS BETWEEN GLUTAMATE MEASURES AND
COGNITIVE DYSFUNCTION
Relatively few studies have investigated relationships between glu-
tamate measures and cognitive dysfunction in schizophrenia. The
most commonly investigated task has been the Wisconsin card
sort test (WCST): in schizophrenia, deficits on this task are asso-
ciated with abnormal activation in the ACC and DLPFC (52).
In a study of 19 patients with chronic schizophrenia at 3 T, poor
performance on the WCST was associated with higher Gln/Glu
ratios in the mPFC (including the ACC) (27). In contrast, a larger
study of 43 patients with chronic schizophrenia at 1.5 T found
that ACC, but not DLPFC, Glx levels were positively associated
with WCST learning potential (42). In first-episode psychosis,
an association between hippocampal, but not DLPFC, glutamate,
and WCST errors was reported (53), and in a small sample of 16
Frontiers in Psychiatry | Schizophrenia November 2013 | Volume 4 | Article 151 | 4
Merritt et al. 1H-MRS glutamate in psychosis
genetic high risk individuals, no correlations between WCST per-
formance and Glx levels in the caudate, ACC, or thalamus were
detected (54).
Other tasks investigated include the Stroop, digit span dis-
tractibility test, auditory verbal learning test (AVLT), N-back task,
Iowa gambling task and verbal fluency test (Table 1). Of these,
there are reports of a positive association between mPFC Gln/Glu
ratio and impairments on the digit span distraction test, which
probes short-term memory and selective attention (27), and of
DLPFC Glx and verbal learning and memory on the AVLT (55).
Overall, the findings have been inconsistent and further studies
with larger sample sizes are required. While the above studies
used a voxel of interest method, using whole brain slice proton
echo planar spectroscopy at 4 T in 30 patients Bustillo et al. (43)
detected a positive correlation between general cognitive perfor-
mance in schizophrenia and Glx. Furthermore, subsequent path
analyses suggested that the relationship between glutamate and
cognitive performance may be associated with negative symptoms
and unemployment (43).
The relationship between glutamate and cognition in schiz-
ophrenia has been further investigated by combining 1H-MRS
with functional magnetic resonance imaging (fMRI) of the blood
oxygen level dependent (BOLD) response to measure changes in
regional brain activation as participants perform cognitive tasks.
In subjects at clinical high risk of developing psychosis, reduc-
tions in thalamic glutamate were correlated with an elevated
BOLD response in the prefrontal cortex during a verbal fluency
task, whereas the converse association was observed in controls
(56). In a study by Valli et al. (57), medial temporal lobe glu-
tamate levels were correlated with hippocampal BOLD response
during an episodic memory task in controls, whereas this cou-
pling was absent in clinical high risk subjects (57). Finally one
study showed that hippocampal Glx was related to inferior frontal
gyrus activation during episodic memory in controls, and sug-
gested that the absence of this positive coupling in medicated
schizophrenia patients may underlie episodic memory deficits,
reflecting the results seen in Valli et al. (57, 58). Further investiga-
tion of the relationships between regional levels of glutamater-
gic metabolites and abnormalities in regional brain activation
during cognitive tasks may provide a more sensitive means to
characterize the relationship between glutamate and cognition in
schizophrenia.
RELATIONSHIPS BETWEEN GLUTAMATE MEASURES AND
SOCIAL AND OCCUPATIONAL FUNCTIONING
Several studies have also reported correlations between brain glu-
tamate levels and overall level of social and occupational func-
tioning (Table 1). In genetically high risk subjects, lower levels of
Glx/Cr in the mPFC were associated with lower levels of over-
all functioning (59). A longitudinal study at 4 T showed that loss
of glutamate and glutamine in the thalamus, but not the ACC,
over 7 years since first presentation correlated with impaired social
functioning (34). In contrast, in first-episode psychosis higher lev-
els of glutamate in the ACC, but not the thalamus, were associated
with worse overall functioning (38), and in chronic schizophrenia
higher DLPFC glutamate levels were also associated with worse
overall functioning (60). Other studies have found no association
between glutamate measures and overall functioning in chronic
schizophrenia (27) or genetic high risk subjects (36).
SUMMARY AND FUTURE DIRECTIONS
1H-MRS studies relating regional glutamate measures to symp-
toms in schizophrenia have produced inconsistent findings. There
may be several methodological reasons for this, including dif-
ferences in the brain region investigated, and between samples
such as medication, illness stage, and symptom severity. The use
of sub-optimal technical approaches such as low field strengths
together with small sample sizes may also underlie the conflicting
findings. A recent study at 4 T indicates that elevations in the
ratio of Gln/Glu are present in schizophrenia patients, consistent
with elevated glutamatergic neurotransmission (18). However the
majority of 1H-MRS studies in schizophrenia use field strengths
<4 T which cannot reliably measure glutamine, and glutamate
and Glx measures cannot be specifically attributed to glutamate
neurotransmission (17). The increasing availability of higher field
strength scanners may resolve some of the apparent inconsistencies
in the literature.
The majority of studies that have investigated relationships
between glutamate levels and symptom severity have applied cor-
relational analysis, usually post hoc to the main study findings.
A few studies have directly compared glutamatergic metabolite
levels in patient groups on the basis of symptom severity, specifi-
cally those who were or were not currently experiencing symptom
exacerbation (48), were or were not in symptomatic remission
following initial treatment (38) or did or did not have treatment-
resistant illness (49). All found higher levels of glutamate or Glx
in the more symptomatic patient group.
The field would benefit from further studies pre-selecting
groups of patients who differ in severity of negative symp-
toms or cognitive impairment, or longitudinal studies com-
paring within-subjects glutamate levels during periods of ill-
ness stability compared to relapse. Studies of the relationships
between cognitive dysfunction and glutamate in schizophre-
nia may benefit from combination with fMRI to determine
the efficiency of glutamate in supporting networks that sub-
serve cognitive function. To date there are only a handful of
published studies of this type. Finally, relationships between
glutamate levels and symptom severity may be indirect; for
example Stone et al. showed that hippocampal glutamate may
interact with striatal dopamine to determine risk of psychosis
(61), and a path analysis has suggested that negative symptoms
may be secondary to poor cognition associated with low brain
Glx (43).
One question is whether baseline levels of glutamate, gluta-
mine, or Glx are predictive of subsequent outcome or response
to treatment in schizophrenia. A recent study showed that ele-
vated frontal Glx at baseline was associated with poor response
after 4 weeks of antipsychotic treatment (62). This is consistent
with the above findings of glutamatergic elevations in patients
with schizophrenia whose symptoms have not responded well to
treatment (38, 49).
The suggestion that symptoms that do not respond well to
conventional antipsychotic treatment may have a glutamatergic
basis (38, 49) warrants further investigation, as compounds that
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target the glutamatergic system may have particular efficacy in
these patients. Meta-analyses conclude that of the agents which
may improve NMDA receptor-mediated neurotransmission, the
NMDAR co-agonist d-serine and the glycine transporter type 1
inhibitor sarcosine reduce total and negative symptoms as an adju-
vant to antipsychotic medication (63, 64). Lamotrigine, which
may inhibit glutamate release, blocks the psychomimetic effects
of ketamine in healthy volunteers (65) and small trials of lamot-
rigine in chronic, often treatment-resistant or clozapine-treated
patients found that it is beneficial in reducing symptoms (63, 66).
Further work is required to determine the relationship between
regional glutamate concentrations and the expression of symp-
toms at different stages of psychotic illness. This area may benefit
from meta-analyses of the previously published findings and from
new studies selecting patient samples a priori on the basis of
symptom severity.
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